Download PDF
Transfusionsmedizin 2020; 10(03): 143-149
DOI: 10.1055/a-1090-0408
Praxistipp

Rekonvaleszentenplasma zur Behandlung von schwerem COVID-19: Rationale und Design einer randomisierten, offenen klinischen Studie von Rekonvaleszentenplasma verglichen mit bestmöglicher supportiver Behandlung (CAPSID-Studie)

Convalescent Plasma for Treatment of Severe COVID-19: Rationale and Designing of a Randomized, Open-Label Clinical Trial of Convalescent Plasma Compared to Best Supportive Care (CAPSID Trial)
Sixten Körper
1   Institut für Klinische Transfusionsmedizin und Immungenetik, Ulm
,
Bernd Jahrsdörfer
1   Institut für Klinische Transfusionsmedizin und Immungenetik, Ulm
,
Thomas Appl
1   Institut für Klinische Transfusionsmedizin und Immungenetik, Ulm
,
Harald Klüter
2   Institut für Transfusionsmedizin und Immunologie, Mannheim
,
Erhard Seifried
3   Institut für Transfusionsmedizin und Immunhämatologie, Frankfurt am Main
,
Hubert Schrezenmeier
1   Institut für Klinische Transfusionsmedizin und Immungenetik, Ulm
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Rekonvaleszentenplasma wurde bei Patienten mit akuten, viralen respiratorischen Erkrankungen mit schwerem Verlauf eingesetzt (SARS- oder MERS-Coronavirus, Influenza H1N1, H5N1). Diese Studien erbrachten Hinweise auf eine Reduktion der Viruslast, einer Verkürzung des Krankenhausaufenthalts und eine Reduktion der Mortalität durch Rekonvaleszentenplasma. Die Wirkung konnte jedoch nicht abschließend belegt werden, da es sich nicht um randomisierte Studien handelte. Nach einer SARS-CoV-2-Infektion kommt es bei den meisten Patienten zu einer raschen Bildung von neutralisierenden Antikörpern. Wegen der pandemischen Entwicklung gibt es eine wachsende Zahl Genesener mit neutralisierenden Antikörpern, die als potenzielle Spender in Betracht kommen. Wir konzipierten eine prospektive, randomisierte Studie, um die Wirksamkeit und Sicherheit von Rekonvaleszentenplasma zur Therapie von schwerem COVID-19 und dessen Wirkmechanismus zu untersuchen (CAPSID-Studie). In diesem Beitrag werden die Rationale und das Design der Studie vorgestellt.

Abstract

Convalescent plasma therapy was administered in patients with acute, viral respiratory disorders with severe clinical course (SARS- or MERS coronavirus, influenza H1N1, H5N1). These studies suggested that convalescent plasma is likely to improve viral clearance, reduce the length of hospital stay and reduce mortality and appeared to be safe. However, since controlled randomized trials were lacking only low-quality evidence was available. Most patients mount a strong humoral immune response early in the course of a SARS-CoV-2 infection, including neutralizing antibodies. Due to the pandemic an increasing number of convalescent patients who are potential donors for SARS-CoV-2 convalescent plasma will be available. We designed a prospective randomized clinical trial to study the safety and efficacy of convalescent plasma for treatment of severe COVID-19 and its mechanism of action (CAPSID trial). Here we present the rationale for this trial and major aspects of the study outline.

Schlüsselwörter

SARS-CoV-2-Infektion - COVID-19 - Rekonvaleszentenplasma - randomisierte klinische Prüfung

Key words

SARS-CoV-2 infection - COVID-19 - convalescent plasma - randomized clinical trial


Publication History

Article published online:
25 August 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5: 536-544
    CrossrefPubMedGoogle Scholar
  • 2 Davis JS, Ferreira D, Denholm JT. et al. Clinical trials for the prevention and treatment of COVID-19: current state of play. Med J Aust 2020; DOI: 10.5694/mja2.50673.
    CrossrefPubMedGoogle Scholar
  • 3 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the Treatment of Covid-19 – Preliminary Report. N Engl J Med 2020; DOI: 10.1056/NEJMoa2007764.
    CrossrefPubMedGoogle Scholar
  • 4 Grein J, Ohmagari N, Shin D. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; 382: 2327-2336
    CrossrefPubMedGoogle Scholar
  • 5 Wang Y, Zhang D, Du G. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569-1578
    CrossrefPubMedGoogle Scholar
  • 6 Horby P, Lim WS, Emberson J. et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv 2020; DOI: 10.1101/2020.06.22.20137273.
    CrossrefPubMedGoogle Scholar
  • 7 Johnson RM, Vinetz JM. Dexamethasone in the management of covid-19. BMJ 2020; 370: m2648 doi:10.1136/bmj.m2648
    CrossrefPubMedGoogle Scholar
  • 8 Spyropoulos AC, Levy JH, Ageno W. et al. Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19. J Thromb Haemost 2020; DOI: 10.1111/jth.14929.
    CrossrefPubMedGoogle Scholar
  • 9 OʼCallaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 Vaccine at Warp Speed. JAMA 2020; DOI: 10.1001/jama.2020.12190.
    CrossrefPubMedGoogle Scholar
  • 10 Paul-Ehrlich-Institut. Funk MB, Heiden M, Müller S. Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2016/17: Auswertung der Meldungen von Reaktionen und Zwischenfällen nach § 63i AMG; 2019. Im Internet (Stand: 23.09.2019): https://www.pei.de/SharedDocs/Downloads/DE/newsroom/pflichtberichte/haemovigilanzberichte/haemovigilanz-bericht-2016-2017.pdf?__blob=publicationFile&v=3
    PubMedGoogle Scholar
  • 11 Hsueh PR, Huang LM, Chen PJ. et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 2004; 10: 1062-1066
    CrossrefPubMedGoogle Scholar
  • 12 Huang LR, Chiu CM, Yeh SH. et al. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. J Med Virol 2004; 73: 338-346
    CrossrefPubMedGoogle Scholar
  • 13 Woo PC, Lau SK, Wong BH. et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol 2004; 11: 665-668
    CrossrefPubMedGoogle Scholar
  • 14 Chen W, Xu Z, Mu J. et al. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J Med Microbiol 2004; 53: 435-438
    CrossrefPubMedGoogle Scholar
  • 15 Chen X, Zhou B, Li M. et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis 2004; 189: 1158-1163
    CrossrefPubMedGoogle Scholar
  • 16 Mo H, Zeng G, Ren X. et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology 2006; 11: 49-53
    CrossrefPubMedGoogle Scholar
  • 17 Shi Y, Wan Z, Li L. et al. Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. J Clin Virol 2004; 31: 66-68
    CrossrefPubMedGoogle Scholar
  • 18 Qiu M, Shi Y, Guo Z. et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect 2005; 7: 882-889
    CrossrefPubMedGoogle Scholar
  • 19 Lee N, Chan PK, Ip M. et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J Clin Virol 2006; 35: 179-184
    CrossrefPubMedGoogle Scholar
  • 20 Zhao J, Wang W, Wang W. et al. Comparison of immunoglobulin G responses to the spike and nucleocapsid proteins of severe acute respiratory syndrome (SARS) coronavirus in patients with SARS. Clin Vaccine Immunol 2007; 14: 839-846
    CrossrefPubMedGoogle Scholar
  • 21 Yang Z, Wang S, Li Q. et al. Determining SARS sub-clinical infection: a longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital. Scand J Infect Dis 2009; 41: 507-510
    CrossrefPubMedGoogle Scholar
  • 22 Li G, Fan Y, Lai Y. et al. Coronavirus infections and immune responses. J Med Virol 2020; 92: 424-432
    CrossrefPubMedGoogle Scholar
  • 23 Park WB, Perera RA, Choe PG. et al. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea. Emerg Infect Dis 2015; 21: 2186-2189
    CrossrefPubMedGoogle Scholar
  • 24 Choe PG, Perera RAPM, Park WB. et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis 2017; 23: 1079-1084
    CrossrefPubMedGoogle Scholar
  • 25 Wölfel R, Corman VM, Guggemos W. et al. Virological assessment of hospitalized cases of coronavirus disease 2019. Nature 2020; 581: 465-469
    CrossrefPubMedGoogle Scholar
  • 26 Guo L, Ren L, Yang S. et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa310.
    CrossrefPubMedGoogle Scholar
  • 27 Robbiani DF, Gaebler C, Muecksch F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020; DOI: 10.1038/s41586-020-2456-9.
    CrossrefPubMedGoogle Scholar
  • 28 Liu W, Liu L, Kou G. et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J Clin Microbiol 2020; DOI: 10.1128/JCM.00461-20.
    CrossrefPubMedGoogle Scholar
  • 29 Jahrsdorfer B, Kroschel J, Ludwig C. et al. Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing. 2020 [submitted]
    PubMedGoogle Scholar
  • 30 Seydoux E, Homad LJ, MacCamy AJ. et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 2020; DOI: 10.1016/j.immuni.2020.06.001.
    CrossrefPubMedGoogle Scholar
  • 31 Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 80-90
    CrossrefPubMedGoogle Scholar
  • 32 Zhou XZ, Zhao M, Wang FS. et al. [Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area]. Zhonghua Yi Xue Za Zhi 2003; 83: 1018-1022
    PubMedGoogle Scholar
  • 33 Soo YO, Cheng Y, Wong R. et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10: 676-678
    CrossrefPubMedGoogle Scholar
  • 34 Cheng Y, Wong R, Soo YO. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44-46
    CrossrefPubMedGoogle Scholar
  • 35 Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2008; 62: 437-441
    CrossrefPubMedGoogle Scholar
  • 36 Nie QH, Luo XD, Hui WL. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome. World J Gastroenterol 2003; 9: 1139-1143
    CrossrefPubMedGoogle Scholar
  • 37 Wong VW, Dai D, Wu AK. et al. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003; 9: 199-201
    PubMedGoogle Scholar
  • 38 Yeh KM, Chiueh TS, Siu LK. et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005; 56: 919-922
    CrossrefPubMedGoogle Scholar
  • 39 Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis 2005; 24: 583-591
    CrossrefPubMedGoogle Scholar
  • 40 Arabi YM, Hajeer AH, Luke T. et al. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis 2016; 22: 1554-1561
    CrossrefPubMedGoogle Scholar
  • 41 Dodd LE, Follmann D, Proschan M. et al. A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Sci Transl Med 2019; 11: 11-520
    CrossrefPubMedGoogle Scholar
  • 42 Katzelnick LC, Gresh L, Halloran ME. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 2017; 358: 929-932
    CrossrefPubMedGoogle Scholar
  • 43 Wan Y, Shang J, Sun S. et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol 2020; DOI: 10.1128/JVI.02015-19.
    CrossrefPubMedGoogle Scholar
  • 44 Dzik S. COVID-19 Convalescent Plasma: Now Is the Time for Better Science. Transfus Med Rev 2020; DOI: 10.1016/j.tmrv.2020.04.002.
    CrossrefPubMedGoogle Scholar
  • 45 Liu L, Wei Q, Lin Q. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019; DOI: 10.1172/jci.insight.123158.
    CrossrefPubMedGoogle Scholar
  • 46 Vorstand der Bundesärztekammer auf Empfehlung seines Wissenschaftlichen Beirats und im Einvernehmen mit dem Paul-Ehrlich-Institut. Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinie Hämotherapie). Köln: Deutscher Ärzteverlag; 2017
    Google Scholar
  • 47 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117: 9490-9496
    CrossrefPubMedGoogle Scholar
  • 48 Shen C, Wang Z, Zhao F. et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA 2020; 323: 1582-1589
    CrossrefPubMedGoogle Scholar
  • 49 Zeng QL, Yu ZJ, Gou JJ. et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients with Coronavirus Disease 2019. J Infect Dis 2020; 222: 38-43
    CrossrefPubMedGoogle Scholar
  • 50 Joyner MJ, Wright RS, Fairweather D. et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest 2020; DOI: 10.1172/JCI140200.
    CrossrefPubMedGoogle Scholar
  • 51 Liu STH, Lin HM, Baine I. et al. Convalescent plasma treatment of severe COVID-19: A matched control study. medRxiv 2020; DOI: 10.1101/2020.05.20.20102236.
    CrossrefPubMedGoogle Scholar